Nkarta (NKTX) Change in Accured Expenses (2019 - 2026)
Nkarta's (NKTX) quarterly Change in Accured Expenses came in at -$3.9 million in Q1 2026, down 2117.71% year-on-year from $192000.0 in Q1 2025, and down 253.37% quarter-over-quarter from $2.5 million in Q4 2025.
Nkarta (NKTX) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Nkarta's Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 2117.71% year-over-year to -$3.9 million in Q1 2026; TTM through Mar 2026 was -$1.6 million, a 29.9% decrease from a year earlier, with the FY2025 full-year figure at $2.5 million, up 155.11% from the prior year.
- Change in Accured Expenses retreated to -$3.9 million in Q1 2026 per NKTX's latest filing, from $2.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $4.6 million in Q3 2022 and bottomed at -$3.9 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $192000.0 (2025), against an average of $64705.9.
- Across the five-year window, Change in Accured Expenses soared 285.08% in 2023 and plunged 2117.71% in 2026, its largest moves.
- Year by year, Change in Accured Expenses stood at -$619000.0 in 2022, then surged by 196.28% to $596000.0 in 2023, then slumped by 512.08% to -$2.5 million in 2024, then surged by 202.85% to $2.5 million in 2025, then tumbled by 253.37% to -$3.9 million in 2026.
- Per Business Quant, the three latest NKTX Change in Accured Expenses figures stand at -$3.9 million (Q1 2026), $2.5 million (Q4 2025), and $448000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | -16.74 Mn |
| 10 | Nkarta | 178.96 Mn | 178.96 Mn | - | -3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.87 Mn |
| Mar 31, 2026 | -3.87 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Jun 30, 2025 | -703,000.00 |
| Jun 30, 2025 | -703,000.00 |
| Mar 31, 2025 | 192,000.00 |
| Mar 31, 2025 | 192,000.00 |
| Dec 31, 2024 | -2.46 Mn |
| Dec 31, 2024 | -2.46 Mn |
| Sep 30, 2024 | 130,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | -3.04 Mn |
| Mar 31, 2024 | -3.04 Mn |
| Dec 31, 2023 | 596,000.00 |
| Dec 31, 2023 | 596,000.00 |